We are live on ! Find out more
VRCA icon

Verrica Pharmaceuticals

58 hedge funds and large institutions have $13.4M invested in Verrica Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $13M → $13.4M (+$396K)

0.52% less ownership

Funds ownership: 3.21%2.69% (-0.52%)

22% less funds holding

Funds holding: 7458 (-16)

50% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 22

53% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 30

Holders
58
Holders Change
-16
Holders Change %
-21.62%
% of All Funds
0.76%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
11
Reduced
22
Closed
30
Calls
Puts
Net Calls
Net Calls Change

VRCA Hedge Fund Activity: Q2 2025 in Review

58 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2025, worth a combined $13.4M — up 3% from $13M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of VRCA and 14 opened new positions — a net loss of 16 holders — while 22 trimmed existing stakes and 11 added.

The largest buyer was Millennium Management, adding an estimated $275K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $1.24M sold.

  • 58 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2025, down from 74 in Q1 2025.
  • Funds reported $13.4M of Verrica Pharmaceuticals stock for Q2 2025, up 3% quarter-over-quarter.
  • 14 funds opened new Verrica Pharmaceuticals positions in Q2 2025 and 30 closed out, a net change of -16 holders.
  • The largest Verrica Pharmaceuticals buyer in Q2 2025 was Millennium Management, an estimated $275K added.
  • The largest Verrica Pharmaceuticals seller in Q2 2025 was Boothbay Fund Management, an estimated $1.24M sold.

Based on aggregated 13F filings for Q2 2025.